Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00096239 · ClinicalTrials.gov registry record · Phase 2
CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00096239: Completed Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00096239 is a Phase 2 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00096239, a Phase 2 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with recurrent or persistent ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Interventions
- DRUG CP-547,632
Trial Details
| Field | Value |
|---|---|
| Start Date | 2004-12 |
| Est. Completion | 2005-02 |
| Phase | Phase 2 |
What the finished NCT00096239 record still lists
NCT00096239 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which CP-547,632 is the first listed.
NCT00096239 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00096239 about?
NCT00096239 is a clinical study titled "CP-547,632 in Treating Patients With Recurrent or Persistent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer". RATIONALE: CP-547,632 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. PURPOSE: This phase II trial is studying how well CP-547,632 works in treating patients with recurrent or persistent ovarian cancer, primary peritonea...
What is the current status of trial NCT00096239?
This trial is currently completed. It is a Phase 2 study. The study started on 2004-12. Estimated completion is 2005-02.
What interventions are being tested in trial NCT00096239?
The interventions under investigation include: CP-547,632 (DRUG).
Who is sponsoring clinical trial NCT00096239?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia